Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference
Rifaquat Rahman(Brigham and Women's Hospital), Mustafa Khasraw(Northwestern University), Carey K. Anders(Duke University), Priscilla K. Brastianos(Massachusetts General Hospital), Evanthia Galanis(Mayo Clinic in Arizona), Patrick Y. Wen(Dana-Farber Cancer Institute), Minesh P. Mehta(Columbia University), John de Groot(University of California, San Francisco), Mei‐Yin C. Polley(Mayo Clinic in Arizona), Laura Alder(Duke Medical Center), Gelareh Zadeh(University Health Network), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Steven Piantadosi(Brigham and Women's Hospital), Susan M. Geyer(Mayo Clinic in Florida)
Cited by 26
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k